Discover
ELTX
Elicio Therapeutics, Inc.
1.96
1 x 1.86
2 x 2.31
bid
ask
+
0.07
3.70%
10:05 AM
timesize
| Ytd | -75.38% | |
| 1y | -82.69% |
1.92
day range
2.00
1.71
52 week range
16.00
| Open | 1.92 | Prev Close | 1.89 | Low | 1.92 | High | 2.00 | Mkt Cap | 51.51M |
| Vol | 66.12K | Avg Vol | 669.17K | EPS | -2.15 | P/E | N/A | Forward P/E | -1.96 |
| Beta | 1.29 | Short Ratio | 2.49 | Inst. Own | 5.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 2.83 | 200-d Avg | 7.72 | 1yr Est | 9.50 |
| Income Statement | |||
| Operating Expenses | 10.43M | ||
| Research and Development Expense | 6.81M | ||
| Selling, General and Administrative Expense | 3.62M | ||
| Operating Income | -10.43M | ||
| Interest Expense | 410.00K | ||
| Net Income | -8.22M | ||
| Net Income Common Stock | -8.22M | ||
| Net Income Common Stock (USD) | -8.22M | ||
| Consolidated Income | -8.22M | ||
| Earnings per Basic Share | -0.43 | ||
| Earnings per Basic Share (USD) | -0.43 | ||
| Earnings per Diluted Share | -0.43 | ||
| Earning Before Interest & Taxes (EBIT) | -7.81M | ||
| Earning Before Interest & Taxes (USD) | -7.81M | ||
| Weighted Average Shares | 19.24M | ||
| Weighted Average Shares Diluted | 19.24M | ||
| Balance Sheet | |||
| Cash and Equivalents | 23.48M | ||
| Cash and Equivalents (USD) | 23.48M | ||
| Current Assets | 25.49M | ||
| Property, Plant & Equipment Net | 4.51M | ||
| Total Assets | 31.33M | ||
| Debt Current | 1.07M | ||
| Total Debt | 14.15M | ||
| Current Liabilities | 9.20M | ||
| Debt Non-Current | 13.08M | ||
| Total Liabilities | 23.39M | ||
| Accumulated Retained Earnings (Deficit) | -253.71M | ||
| Accumulated Other Comprehensive Income | -126.00K | ||
| Shareholders Equity | 7.94M | ||
| Shareholders Equity (USD) | 7.94M | ||
| Assets Non-Current | 5.85M | ||
| Total Debt (USD) | 14.15M | ||
| Liabilities Non-Current | 14.19M | ||
| Trade and Non-Trade Payables | 839.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 283.00K | ||
| Net Cash Flow from Financing | 16.51M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 8.34M | ||
| Issuance (Purchase) of Equity Shares | 16.51M | ||
| Net Cash Flow from Operations | -8.16M | ||
| Effect of Exchange Rate Changes on Cash | -4.00K | ||
| Share Based Compensation | 935.00K | ||